Ahmedabad-based Torrent Pharma is in talks to acquire select businesses from Novartis India in a deal estimated to be less than Rs 500 crore. Torrent’s plan for acquisition comes at a time when its sales in the US market have declined by 51 per cent in the nine months ended December. Novartis has drugs in pain management and diabetes care that it considers core. It also has drugs to cure tuberculosis and other infectious diseases. “The discussions between Torrent and Novartis are expected to be finalised in a month,” said an investment banker familiar ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?